FHAI, TTEG, UBRG, WLDN, YMI, KBLB OTCPicks.com Stocks to Watch for Wednesday, August 26th

Our Stocks to Watch tomorrow include Fountain Healthy Aging Inc. (OTCBB: FHAI), Turbine Truck Engines Inc. (OTCBB: TTEG), Universal Bioenergy Inc. (OTC: UBRG), Willdan Group Inc. (Nasdaq: WLDN), YM BioSciences Inc. (Amex: YMI) and Kraig Biocraft Laboratories Inc. (OTCBB: KBLB).

Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover's Digest Newsletter, and Email Stock Watch Alerts.

FOUNTAIN HEALTHY AGING INCORPORATED (OTCBB: FHAI)

"Up 1,284.61% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/FHAI.php 

Fountain Healthy Aging is a company specifically focussed in the anti aging industry, which is one of the quickest growing industry sectors worldwide. We have a range of products targeted at the anti-aging market, including our revolutionary flagship product Vitalife, which we believe is ready to make a massive impact in the anti-aging industry. We recognize the importance of the anti-aging sector, an emerging dynamic within the overall health and wellness revolution. We believe that we are uniquely positioned to capitalize on this rapidly growing trend, first with our unique flagship product, rapidly followed by our other products which have been specifically developed for this market. Fountain Healthy Aging's main focus is on the specialty, premium product category, which is a growing segment of the market that provides gross margins significantly higher that the lower-priced, mainstream health products market.

FHAI News:

August 12 - Fountain Healthy Aging Inc Announces $5,000,000 Equity Line Of Credit Investment Secured

Fountain Healthy Aging Inc. (OTCBB: FHAI) announced on August 12 2009 that it had entered into an agreement with Dunn Capital Partners and Oak Resources Limited which provides the Company with a $5,000,000 Equity Line of Credit investment. Under the terms of the agreement, Fountain has the right to draw down from the Equity Line Investment in tranches of up to $1,000,000 each, for a term of 24 months. The first tranche investment of $1,000,000 was drawn down by Fountain on August 10 2009.

Fountain CEO, Paul Hunston, said "We are very pleased to have secured this $5,000,000 equity line of credit, which will enable us to fully implement our business plan and accelerate the Company's growth both within the US and internationally. This is great news for both Fountain and its shareholders."

Michael Bailey, head of Equity Capital markets at Dunn Capital Partners said: "We take pride in our ability to identify companies with strong management teams, growth potential and competitive advantages. We are delighted that through Oak Resources, we have been able to make this investment in Fountain. We think Fountain is perfectly positioned to leverage its high quality and natural product range and take advantage of its unique positioning in the market place. We look forward to working with Oak Resources and Fountain in helping the Company realize and execute its full growth potential."

ABOUT DUNN CAPITAL PARTNERS

Dunn Capital Partners is a private investment company and is focused on investing in growing Small Cap issuers with solid fundamentals.

Dunn Capital Partners typically invests anywhere from $10,000,000 to $250,000,000+ with companies seeking a long-term funding partner and a strategic partner to support its growth.

Dunn Capital Partners is committed to investing in companies with strong management who have the ability to execute their business plan upon the receipt of growth capital.

Dunn Capital Partners is industry and geography agnostic.

TURBINE TRUCK ENGINES INCORPORATED (OTCBB: TTEG)

"Up 13.50% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/TTEG.php

Turbine Truck Engines, Inc. is a technology company focused on the development, manufacture, and testing of its New Energy and Environmental Efficient Truck Engine intended for mass markets in the United States and abroad. This new engine design can utilize any known fuel source (gasoline, diesel, propane, natural gas, hydrogen, methanol, ethanol, or LPG) or fuel mixture, yet needs no coolant, lube, oil, filters, or pumps. The unique, lightweight turbine design has few moving parts, significantly reducing maintenance costs. The innovative cyclical detonation process produces a complete combustion of fuel-oxidation mixtures, resulting in greater fuel economy and few harmful exhaust emissions.

TTEG News:

August 24 - Strategic Alliance Between Turbine Truck Engines and AMEC Gains Momentum

In January 2009, Turbine Truck Engines, Inc. (OTCBB: TTEG) (TTE) and China's Aerospace Machinery and Electric Equipment Co. Ltd. (AMEC) entered into a strategic alliance, agreeing to collaborate on the engineering and technical development of the patented Detonation Cycle Gas Turbine Engine (DCGT). TTE also granted AMEC the exclusive license to commercialize the engine in China's automotive and busing markets when the design process is completed. TTE has learned that AMEC will have full access to the resources of Shenyang Aerospace Mitsubishi Motors Engine Manufacturing Co., Ltd. (Aerospace Mitsubishi) in the engineering and development process.

Aerospace Mitsubishi is a joint venture (JV) between five companies from China, Japan, and Malaysia. AMEC's sister corporation, China Aerospace Automotive Industry Group (Aerospace Automotive), has a 30% stake in the JV, and Aerospace Automotive will be the channel through which AMEC will access Aerospace Mitsubishi resources. AMEC intends to develop 150 and 400 horsepower versions of the DCGT. Once developed, the engine will be manufactured in Aerospace Mitsubishi's state-of-the-art engine assembly plant. The plant is already producing 100,000 engines annually, and is expected to reach 15 million units annually when the facility is complete.

AMEC and Aerospace Automotive are wholly owned subsidiaries of China Aerospace Science and Industry Corp (CASIC). CASIC (www.casic.com.cn) is one of the largest state owned enterprises in China and employs more than 100,000 people, over 40% of which are technical and engineering personnel. CASIC is comprised of seven research institutions, two manufacturing bases, and several production enterprises. Of the 150 CASIC subsidiaries, six are publicly traded companies on the Hong Kong and China Exchanges. The corporation is responsible for the development of China's space program and is considered the most technically advanced enterprise in China.

Michael Rouse, President and CEO of TTE, is in China for high-level meetings with AMEC officials, and he observed, "AMEC's access to Aerospace Mitsubishi's resources will speed the process to which we are mutually committed, and I am excited about the implications of this development for all TTE and AMEC stakeholders."

UNIVERSAL BIOENERGY INCORPORATED (OTC: UBRG)

"Up 814.29% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/UBRG.php

Universal Bioenergy Inc. is an alternative "Green Energy" company, and intends to create and market alternative energy sources including Biofuels, Wind, Solar, Synthetic Fuels and other related energy technology products. It plans to build the company into a prominent player in what is quickly becoming one of the most important industries of our century — alternative green energy.

UBRG News:

August 25 - Universal Bioenergy Signs Multi-Million Dollar Biofuels Contract

Universal Bioenergy Inc. (OTC: UBRG) a company focused on the development and production of alternative energy sources and green technologies, announced today that it has signed a multi-million dollar contract with Mississippi Investment Petroleum Company (MIPCO), a next generation biofuels energy producer and marketer.

Under the terms of the agreement MIPCO will have a biodiesel fuel production arrangement and lease of Universal Bioenergy's biodiesel fuel refinery in Nettleton, Mississippi to produce and distribute biodiesel fuel to the Southeast, Midwest and Gulf Coast regions of the United States. The estimated gross revenue to be generated from the fuel sales to the end user is $30 million. The gross operating profit to Universal Bioenergy is estimated at $3 million, with a net profit of $2.4 million per year, since the company will incur no operating costs other than general and administrative expenses. Universal Bioenergy is currently debt free and the current market value of its refinery plant at full operation is estimated at $13+ million.

Their Chief Executive Officer Dr. Richard Craven states, "This contract will be very favorable to Universal Bioenergy, in terms of our revenue, growth, expansion goals and to secure similar contracts with other firms in the future." It is projected that the refinery would be producing fuel in November of this year, and would produce about 12 millions gallons per year at current capacity.

WILLDAN GROUP INCORPORATED (NASDAQ: WLDN)

"Up 116.76% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/WLDN.php 

Founded over 40 years ago, Willdan Group, Inc. is a provider of outsourced and consulting services to public agencies located primarily in California and other western states. Willdan Group, Inc. assists cities and other government agencies and, to a lesser extent, private industry and public utilities with a broad range of services, including civil engineering, building and safety services, geotechnical engineering, energy efficiency, water conservation, renewable resource strategy, financial and economic consulting, and disaster preparedness and homeland security.

WLDN News:

August 20 - Willdan Awarded $67 Million Contract by Con Edison

Company to Implement Major Small Business Energy Efficiency Program

Willdan Group, Inc. (Nasdaq: WLDN) (“Willdan”) announced that its wholly-owned subsidiary, Willdan Energy Solutions (WES), was awarded a $67 million contract with Consolidated Edison Company of New York, Inc., (Con Edison), a subsidiary of Consolidated Edison, Inc. (NYSE: ED), to implement Con Edison’s new energy efficiency program for small business customers. The initial contract work will commence in the current quarter, with most of the work scheduled to be completed by the end of 2011.

The program is one of several designed by Con Edison to help the State of New York achieve its energy and greenhouse gas emissions reduction goals. It will offer small business customers free energy surveys, pay up to 70 percent of the installed cost for most energy-saving measures, and install, at no charge to the customer, equipment such as compact fluorescent lamps, water faucet aerators, and high pressure rinse valves.

As the program implementation contractor, WES’ responsibilities will span marketing outreach, completing on-site energy efficiency surveys, implementing energy-saving projects, and partnering with the community and local businesses. A pioneer in the nation’s energy efficiency and water conservation activities, WES has paced the industry in managing programs and projects that result in substantial energy savings. Its rapid growth has been fostered by its exceptional engineering expertise, versatility, solid management acumen, and innovative solutions to their clients’ challenges.

“WES has implemented and managed some of the most successful energy efficiency programs in the country,” explains WES President, Jay Bhalla. “We look forward to leveraging our expertise in support of Con Edison’s ambitious energy efficiency program, as well as enlarging the footprint of Willdan’s Northeast Operations.”

ABOUT WILLDAN ENERGY SOLUTIONS

WES is one of the nation’s preeminent energy efficiency and sustainability consultant firms, providing specialized energy, water, and resource management services to create innovative and effective solutions to challenging problems. WES’ subject matter experts and key staff—with more than 20 years combined experience in the energy, sustainability, and information technology fields—provide services that include energy efficiency and water conservation project implementation, sustainability and renewable energy design, and information technology for the utility industry. WES also provides hardware retrofits and retro-commissioning activities for large commercial, lodging, and medical facilities; introduces and develops markets for new technologies; and provides energy efficiency education and coordinates local government partnerships.

WES works with utilities on energy efficiency program design, provides mechanical and electrical engineering support services, conducts audits, and consults with clients on corporate energy initiatives, sustainability, and administering conservation programs. In addition, WES conducts energy analysis and financial return on investment discoveries, and provides energy efficiency education and training services to client employees.

ABOUT CON EDISON

Con Edison is a subsidiary of Consolidated Edison, Inc. (NYSE: ED), one of the nation’s largest investor-owned energy companies, with approximately $14 billion in annual revenue and $34 billion in assets. The utility provides electric, gas and steam service to more than 3 million customers in New York City and Westchester County, New York.

YM BIOSCIENCES INCORPORATED (AMEX: YMI)

"Up 67.85% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/YMI.php

YM BioSciences Inc. is a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development. The Company is currently developing two late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody™, and AeroLEF®, a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

YMI News:

August 10 - YM Biosciences USA Receives Clearance From Us Treasury Department to Extend Clinical Program for Nimotuzumab

YM BioSciences Inc. (Amex: YMI) (TSX: YM) (AIM: YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today announced that its wholly-owned subsidiary, YM BioSciences USA Inc. (YM-USA) has received a license from the US Department of the Treasury's Office of Foreign Assets Control (OFAC) to further develop its lead product, nimotuzumab, for patients with solid tumor cancers in the United States.

"This license from OFAC to develop nimotuzumab in any cancer indication is a major step forward in our US development program and will allow us to immediately discuss our IND submissions with the FDA to include US patients in our randomized, double-blinded lung cancer and brain metastases trials," said David Allan, Chairman and CEO of YM BioSciences. "Our development plans may also include extending some of the Phase III trials being conducted worldwide into the US. There are quantifiable physical, emotional and financial costs that result from the numerous and severe toxicities of the currently available EGFR-targeting drugs which are not evident with the administration of our drug. Nimotuzumab has been demonstrating efficacy in trials throughout the world and we are very pleased that US patients will now have the opportunity to receive the drug and that a broader group of US oncologists will gain experience with it. Our goal is to bring this therapeutic option, already approved for marketing in 18 countries, to patients in the US as rapidly as possible."

Mr. Allan added, "We have also applied to OFAC for a license to make nimotuzumab available to US patients upon marketing approval by the FDA. This is consistent with a 2009 Staff Report to the US Senate Committee on Foreign Relations (SCFR) entitled 'Changing Cuba Policy - In the United States' National Interest,' which recommended pharmaceutical imports from Cuba's rapidly developing biotech industry. We are most appreciative of the extensive support we have received for our application from SCFR Chairman Senator John Kerry (D-MA), Western Hemisphere Subcommittee Chairman Senator Chris Dodd (D-CT) and SCFR Ranking Member Senator Richard Lugar (R-IN) and for their acute understanding of the needs of cancer patients. Such licenses have been previously granted to two companies seeking to commercialize Cuban-origin therapeutics in the US and we have ongoing discussions with OFAC in this regard."

YM USA previously received a license from OFAC to import nimotuzumab into the US to conduct a study of nimotuzumab in children suffering from recurrent diffuse intrinsic pontine glioma. This trial is ongoing at 10 of the principal oncology hospitals in the US and data is expected in 2010. Nimotuzumab is also available on a compassionate use basis in the US for children with this condition and is designated an Orphan Drug for adult and pediatric glioma by the FDA as well as the EMEA for Europe.

Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR), licensed to YM's majority-owned subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and developed at the Center of Molecular Immunology in Cuba. The drug has demonstrated efficacy in clinical trials without the serious side effects observed with the marketed EGFR-targeting drugs. Nimotuzumab has been administered to approximately 5,000 patients worldwide and is currently in 32 trials internationally of which 11 are being conducted by YM and its four licensees. Three of the latter are Phase III trials, including one being conducted by the internationally recognized National Cancer Center of Singapore, which selected nimotuzumab over the alternative antibodies because of its benign side effect profile.

KRAIG BIOCRAFT LABORATORIES INCORPORATED (OTCBB: KBLB)

"Up 53.57% on Tuesday"

Detailed Quote: http://www.otcpicks.com/quotes/KBLB.php 

Kraig Biocraft Laboratories, Inc. focuses on the development of protein based fiber using recombinant DNA technology for commercial applications in the textile and specialty fiber industries. Its products are used in military and police departments; industrial applications, including critical cables and abrasion/impact resistant components; and consumer applications. These fibers are also employed in safety equipment, and high strength composite materials for the aero-space industry. The company was founded in 2006 and is based in Lansing, Michigan.

KBLB News:

August 3 - Kraig Biocraft Laboratories, Inc. Greatly Exceeds Its Performance Goals

Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) announced that during the months of May, June and July the scientific team succeeded in its previously announced attempt to ramp up the number of genetic insertions performed. The team’s initial goal was to double the number of DNA construct insertions performed in May. The Company is very happy to report that the actual number of insertions performed greatly exceeded that goal and that the increase was sustained in June and July as well.

“Over the last ninety days, Dr. Fraser’s team has performed tens of thousands of DNA construct insertions. This increase in laboratory productivity greatly exceeded management’s expectations for the period,” said CEO Kim K. Thompson. “This dramatic increase in productivity is an indication of the dedication and enthusiasm of the scientists. We know that each insertion has the potential to create a new recombinant fiber with commercial applications.”

OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.This email address is being protected from spam bots, you need Javascript enabled to view it.

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stockbroker before investing.

Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward-looking statements. These forward-looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward-looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company's operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.

Disclosure: OTCPicks.com has been compensated three thousand dollars by a third party (Blue Wave Advisors) for one week of UBRG advertising and promotional activities. OTCPicks.com has been compensated one hundred twenty thousand free trading shares by a non-controlling third party (Quality Stocks) for a KBLB advertising and promotional program.